Signaturefd LLC Buys 2,541 Shares of Galapagos NV (NASDAQ:GLPG)

Signaturefd LLC increased its stake in shares of Galapagos NV (NASDAQ:GLPG) by 65.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,413 shares of the biotechnology company’s stock after acquiring an additional 2,541 shares during the quarter. Signaturefd LLC’s holdings in Galapagos were worth $185,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Creative Planning acquired a new stake in shares of Galapagos in the 2nd quarter valued at about $456,000. Headlands Technologies LLC grew its stake in Galapagos by 56.7% in the second quarter. Headlands Technologies LLC now owns 1,233 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 446 shares during the period. Stonepine Capital Management LLC grew its stake in Galapagos by 23.2% in the second quarter. Stonepine Capital Management LLC now owns 485,000 shares of the biotechnology company’s stock valued at $12,018,000 after acquiring an additional 91,366 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Galapagos by 783.6% during the first quarter. BNP Paribas Financial Markets now owns 5,328 shares of the biotechnology company’s stock valued at $172,000 after acquiring an additional 4,725 shares in the last quarter. Finally, Acadian Asset Management LLC raised its position in shares of Galapagos by 18.5% during the first quarter. Acadian Asset Management LLC now owns 15,186 shares of the biotechnology company’s stock worth $488,000 after purchasing an additional 2,366 shares during the period. 32.46% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on GLPG. Leerink Partnrs raised shares of Galapagos to a “hold” rating in a research report on Monday, September 9th. Leerink Partners assumed coverage on shares of Galapagos in a report on Monday, September 9th. They set a “market perform” rating and a $24.00 price objective for the company. Finally, Raymond James lowered shares of Galapagos from an “outperform” rating to a “market perform” rating in a report on Friday, August 2nd. One analyst has rated the stock with a sell rating and five have given a hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $31.00.

Galapagos Stock Performance

Galapagos stock opened at $28.95 on Monday. Galapagos NV has a fifty-two week low of $24.16 and a fifty-two week high of $42.46. The firm’s 50-day simple moving average is $28.97 and its 200 day simple moving average is $27.78.

Galapagos Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.